

CP380E

PATENT

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-23. (canceled)

24. (new) A method of treating cancer in a human, which comprises administering to the human a combination of (i) a therapeutically effective amount of one or more arsenic compounds, and (ii) radiation.

25. (new) The method of claim 24, wherein said arsenic compound is arsenic trioxide.

26. (new) The method of claim 25, wherein the arsenic trioxide is formulated as an ionic aqueous solution.

27. (new) The method of claim 24, wherein the total daily amount administered of the arsenic compound is from about 10 g to about 200 mg.

28. (new) The method of claim 24, wherein the total daily amount administered of the arsenic compound is from about 0.5 mg to about 150 mg.

29. (new) The method of claim 24, wherein the total daily amount administered of the arsenic compound is from about 0.5 mg to about 70 mg.

30. (new) The method of claim 24, wherein the arsenic compound is administered parenterally.

31. (new) The method of claim 24, wherein the arsenic compound is administered intravenously.

32. (new) The method of claim 24, wherein the radiation and the arsenic compound are administered in combination with an effective amount of at least one further therapeutic agent.

CP380E

PATENT

33. (new) The method of claim 32, wherein the further therapeutic agent is a chemotherapeutic or radiotherapeutic.
34. (new) The method of claim 32, wherein the further therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26(vumon), BCNU, all-trans retinoic acid, procarbazine, cytokines, therapeutic vaccines, and immunomodulators.
35. (new) The method of claim 25, wherein the dose is varied according to the body weight of the human.
36. (new) The method of claim 25, wherein the cancer is a hematopoietic cancer.
37. (new) The method of claim 25, wherein the cancer is a leukemia.
38. (new) The method of claim 37, wherein the leukemia is an acute myelogenous leukemia.
39. (new) The method of claim 37, wherein the leukemia is a chronic myelogenous leukemia.
40. (new) The method of claim 25, wherein the cancer is a lymphoma.
41. (new) The method of claim 25, wherein the cancer is a solid tumor.
42. (new) The method of claim 25, wherein the cancer has metastasized.
43. (new) The method of claim 25, wherein the radiation is administered prior to the arsenic trioxide.

CP380E

PATENT

44. (new) The method of claim 25, wherein the radiation is administered after to the arsenic trioxide.

45. (new) The method of claim 25, wherein the radiation and the arsenic trioxide are administered concurrently.

46. (new) The method of claim 25, wherein said cancer is a tumor of the central nervous system selected from the group consisting of neuroblastoma, retinoblastoma, glioblastoma or oligodendroglioma.